Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
Gonçalves
Anthony
A
Monges
Genevieve
G
Yang
Ying
Y
Palmerini
Fabienne
F
Dubreuil
Patrice
P
Noguchi
Tetsuro
T
Jacquemier
Jocelyne
J
Di Stefano
Donatella
D
Delpero
Jean-Robert
JR
Sobol
Hagay
H
Bertucci
Francois
F
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D005260:Female; D005350:Fibroma / Q000737:chemistry; D018095:Germ-Line Mutation; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis* / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000032:analysis / Q000235:genetics
D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha